Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02025998 · ClinicalTrials.gov registry record · Phase 1
Development of Ibudilast for Alcohol Use Disorder
A Phase 1 study, sponsored by University of California, Los Angeles.
- Completed
- Registry status
- Phase 1
- Development phase
- 24
- Enrollment target
NCT02025998 is a Phase 1 study that has completed, run by University of California, Los Angeles. The registered enrollment target is 24 participants.
The verdict
NCT02025998, a Phase 1 study, has completed, sponsored by University of California, Los Angeles.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 24 participants
- Enrollment target
Study Summary
The objective of this proposal is to advance medication development for alcoholism by conducting a safety and initial efficacy study of ibudilast, a neuroimmune modulator and phosphodiesterase inhibitor, for alcohol use disorders.
Interventions
- DRUG Ibudilast
- OTHER Matched placebo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2013-12 |
| Est. Completion | 2015-06 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02025998
The ClinicalTrials.gov registry entry for NCT02025998 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of California, Los Angeles, which has 897 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Ibudilast is the first listed.
NCT02025998 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02025998 about?
NCT02025998 is a clinical study titled "Development of Ibudilast for Alcohol Use Disorder". The objective of this proposal is to advance medication development for alcoholism by conducting a safety and initial efficacy study of ibudilast, a neuroimmune modulator and phosphodiesterase inhibitor, for alcohol use disorders.
What is the current status of trial NCT02025998?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 24 participants. The study started on 2013-12. Estimated completion is 2015-06.
What interventions are being tested in trial NCT02025998?
The interventions under investigation include: Ibudilast (DRUG), Matched placebo (OTHER).
Who is sponsoring clinical trial NCT02025998?
This trial is sponsored by University of California, Los Angeles, which has 897 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.